While the difference was not dramatic (~3 points, which is well below the minimally clinically important difference in the MDS-UPDRS-3 of around ~5 points), it appeared to remain after a 2-month washout period, intended to support the idea that, because the improvements remained after removal of the incretin, the difference should be a disease-modifying, rather than a symptomatic benefit
Even though its unlikely to cause serious toxicity or injury, you have to ask yourself if its worth it to put this form of B12 into your body knowing that it must be eliminated and detoxified
If youre curious about how these injections might fit into your broader health strategy or have any other questions, please reach out to us at (972) 808-5146
Protecting groups such as t-Butyloxycarbonyl (t-Boc) or Fmoc are usually used
For that reason, BPC-157 should be described as a multimodal research peptide with several reported downstream pathway associations, rather than as a peptide with a fully defined target and mechanism of action